<DOC>
	<DOC>NCT02260076</DOC>
	<brief_summary>To assess the safety and tolerance of 5 mL to 20 mL PEG 400 in multiple rising doses</brief_summary>
	<brief_title>Safety of Total Daily Doses of Polyethylene Glycol (PEG) 400 Administered Orally to Healthy Male Human Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male subjects as determined by results of screening Signed written informed consent in accordance with good clinical practice (GCP) and local legislation Age ≥ 18 and ≤ 55 years Broca ≥ 20 % and ≤ + 20 % Any finding of the medical examination (including blood pressure, pulse rate and electrocardiogram [ECG]) deviating from normal and of clinical relevance History of current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hormonal disorders, including a clinical history of viral hepatitis, or serological evidence of active Hepatitis B or Hepatitis C infection History of orthostatic hypotension, fainting spells and blackouts Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders Chronic or relevant acute infections History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator Intake of drugs with a long halflife (&gt; 24 hours) within one month prior to administration Use of any drugs which might influence the results of the trial within 10 days prior to administration or during the trial Participation in another trial with an investigational drug within one month prior to administration or during the trial Smoker (&gt; 10 cigarettes or three cigars or three pipes/day) or inability to refrain from smoking 10 hours before the morning dose and one hour before afternoon/evening dose and one hour after any dose Alcohol abuse (&gt; 60 g/day) Drug abuse Blood donation within one month prior to administration or during the trial Excessive physical activities within five days prior to administration or during the trial Any laboratory value outside the clinically accepted reference range and of clinical relevance</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>